Total reported value
$6.1B
Reporting period: 2026-03-31 · Number of holdings: 63
Deep Track Capital, LP disclosed 63 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $6.1B and a quarterly turnover rate of 40.0%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "D"
Trim CYTK
-58.8% -$121.5M
Trim GPCR
+4.1% -$79.7M
Trim MAZE
-18.1% -$72.1M
Trim BMRN
-50.0% -$71.7M
Add 260
+57.9% $75.4M
Add ALKS
+79.5% $71.0M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 20.86% | -0.88% | — | |
| 2 | GH | Guardant Health INC | Stock-Healthcare | 5.04% | -0.06% | +19.22% | |
| 3 | IMVT | Immunovant INC | Stock-Other | 4.68% | — | — | |
| 4 | TARS | Tarsus Pharmaceuticals INC | Stock-Other | 4.12% | — | +19.84% | |
| 5 | PCVX | Vaxcyte INC | Stock-Other | 4.08% | +0.79% | +7.50% | |
| 6 | GPCR | Structure Therapeutics INC | Stock-Other | 3.37% | -1.73% | +4.09% | |
| 7 | AXSM | Axsome Therapeutics INC | Stock-Healthcare | 3.04% | -0.70% | -4.35% | |
| 8 | APLSUSD | Apellis Pharmaceuticals INC | Stock-Other | 2.98% | -0.49% | -41.52% | |
| 9 | OCUL | Ocular Therapeutix INC | Stock-Other | 2.72% | +0.97% | +143.93% | |
| 10 | VERA | Vera Therapeutics INC | Stock-Other | 2.70% | +0.15% | +45.55% | |
| 11 | ALMS | Alumis INC | Stock-Other | 2.44% | +2.44% | NEW | |
| 12 | IONS | Ionis Pharmaceuticals INC | Stock-Healthcare | 2.39% | -0.01% | +14.71% | |
| 13 | NUVL | Nuvalent Inc-a | Stock-Other | 2.30% | +2.30% | NEW | |
| 14 | ALKS | Alkermes plc | Stock-Healthcare | 2.07% | +1.07% | +79.52% | |
| 15 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.05% | +1.16% | +57.90% | |
| 16 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.95% | +0.87% | +39.02% | |
| 17 | MAZE | Maze Therapeutics INC | Stock-Other | 1.70% | -1.44% | -18.11% | |
| 18 | ORKA | Oruka Therapeutics INC | Stock-Other | 1.63% | +0.46% | -5.89% | |
| 19 | NRIX | Nurix Therapeutics INC | Stock-Other | 1.61% | -0.77% | -9.82% | |
| 20 | GMAB | Genmab A/s -sp Adr | Stock-Other | 1.61% | +1.60% | NEW | |
| 21 | CYTK | Cytokinetics INC | Stock-Healthcare | 1.48% | -2.30% | -58.82% | |
| 22 | GRAL | Grail INC | Stock-Healthcare | 1.45% | — | +68.44% | |
| 23 | LBRX | Lb Pharmaceuticals INC | Stock-Other | 1.35% | — | — | |
| 24 | MBX | Mbx Biosciences INC | Stock-Other | 1.34% | -0.49% | -15.15% | |
| 25 | BCAX | Bicara Therapeutics INC | Stock-Other | 1.32% | +0.54% | +55.41% | |
| 26 | CMPS | Compass Pathways PLC | Stock-Other | 1.10% | +0.20% | +65.82% | |
| 27 | BMRN | Biomarin Pharmaceutical INC | Stock-Healthcare | 1.06% | -1.38% | -50.00% | |
| 28 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 1.02% | — | +3.86% | |
| 29 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.95% | -0.29% | -3.60% | |
| 30 | TNGX | Tango Therapeutics INC | Stock-Other | 0.94% | +0.55% | +12.04% | |
| 31 | DFTX | Definium Therapeutics INC | Stock-Other | 0.93% | +0.93% | NEW | |
| 32 | 430 | Terns Pharmaceuticals INC | Stock-Other | 0.92% | +0.37% | +39.64% | |
| 33 | GERN | Geron CORP | Stock-Other | 0.77% | — | -2.43% | |
| 34 | ANIP | Ani Pharmaceuticals INC | Stock-Other | 0.75% | — | +25.61% | |
| 35 | CRMD | Cormedix INC | Stock-Other | 0.70% | -0.39% | +18.96% | |
| 36 | ATAI | Ataibeckley INC | Stock-Other | 0.69% | +0.69% | NEW | |
| 37 | CLDX | Celldex Therapeutics INC | Stock-Other | 0.67% | -0.25% | -32.45% | |
| 38 | COGT | Cogent Biosciences INC | Stock-Other | 0.63% | +0.34% | +120.70% | |
| 39 | CRVS | Corvus Pharmaceuticals INC | Stock-Other | 0.60% | +0.60% | NEW | |
| 40 | DYN | Dyne Therapeutics INC | Stock-Other | 0.59% | -0.33% | -24.53% | |
| 41 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 0.59% | -0.24% | +7.87% | |
| 42 | ACRS | Aclaris Therapeutics INC | Stock-Other | 0.57% | +0.57% | NEW | |
| 43 | MANE | Veradermics INC | Stock-Other | 0.52% | +0.52% | NEW | |
| 44 | VSTM | Verastem INC | Stock-Other | 0.50% | -0.29% | — | |
| 45 | ✓ | Engene Holdings INC | Stock-Other | 0.49% | — | — | |
| 46 | VRDN | Viridian Therapeutics INC | Stock-Other | 0.45% | -0.95% | -44.79% | |
| 47 | XFOR | X4 Pharmaceuticals INC | Stock-Other | 0.43% | — | +26.45% | |
| 48 | SLDB | Solid Biosciences INC | Stock-Other | 0.42% | +0.42% | NEW | |
| 49 | ENTA | Enanta Pharmaceuticals INC | Stock-Other | 0.40% | — | — | |
| 50 | APGE | Apogee Therapeutics INC | Stock-Other | 0.39% | +0.39% | NEW |
Performance for Q3 2026
+23%
Performance Last 4 Quarters
+100.3%
Based on 79% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 63 | $6.1B | 40 | |
| 2025-12-31 | 55 | $5.6B | 87 | |
| 2025-09-30 | 56 | $3.6B | 70 | |
| 2025-06-30 | 66 | $3.1B | 0 | |
| 2025-03-31 | 69 | $3.1B | 0 | |
| 2024-12-31 | 63 | $2.7B | 0 | |
| 2024-09-30 | 71 | $3.2B | 0 | |
| 2024-06-30 | 68 | $3.4B | 0 | |
| 2024-03-31 | 66 | $3.5B | 0 | |
| 2023-12-31 | 60 | $3.0B | 0 | |
| 2023-09-30 | 63 | $2.6B | 0 | |
| 2023-06-30 | 55 | $2.2B | 0 | |
| 2023-03-31 | 58 | $2.4B | 0 | |
| 2022-12-31 | 60 | $2.4B | 0 | |
| 2022-09-30 | 65 | $2.2B | 0 | |
| 2022-06-30 | 51 | $1.5B | 0 | |
| 2022-03-31 | 52 | $1.6B | 0 | |
| 2021-12-31 | 55 | $1.4B | 0 |
Deep Track Capital, LP's most significant position changes for 2026-03-31: Sold out: Dynavax Technologies CORP (DVAX); New buy: Alumis INC (ALMS); New buy: Nuvalent Inc-a (NUVL); New buy: Genmab A/s -sp Adr (GMAB); New buy: Definium Therapeutics INC (DFTX).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 260 | Centessa Pharmaceuticals-adr | +1.2% | +57.90% | Add |
| 2 | ALKS | Alkermes plc | +1.1% | +79.52% | Add |
| 3 | OCUL | Ocular Therapeutix INC | +1% | +143.93% | Add |
| 4 | MLTX | Moonlake Immunotherapeutics | +0.9% | +39.02% | Add |
| 5 | PCVX | Vaxcyte INC | +0.8% | +7.50% | Add |
| 6 | TNGX | Tango Therapeutics INC | +0.6% | +12.04% | Add |
| 7 | BCAX | Bicara Therapeutics INC | +0.5% | +55.41% | Add |
| 8 | ORKA | Oruka Therapeutics INC | +0.5% | -5.89% | Trim |
| 9 | 430 | Terns Pharmaceuticals INC | +0.4% | +39.64% | Add |
| 10 | COGT | Cogent Biosciences INC | +0.3% | +120.70% | Add |
| 11 | JANX | Janux Therapeutics INC | +0.3% | +1225.26% | Add |
| 12 | CMPS | Compass Pathways PLC | +0.2% | +65.82% | Add |
| 13 | VERA | Vera Therapeutics INC | +0.2% | +45.55% | Add |
| 14 | IONS | Ionis Pharmaceuticals INC | 0% | +14.71% | Add |
| 15 | GH | Guardant Health INC | -0.1% | +19.22% | Add |
| 16 | SLNOEUR | Soleno Therapeutics INC | -0.2% | +7.87% | Add |
| 17 | CLDX | Celldex Therapeutics INC | -0.3% | -32.45% | Trim |
| 18 | VSTM | Verastem INC | -0.3% | — | Unchanged |
| 19 | IMCR | Immunocore Holdings Plc-adr | -0.3% | -3.60% | Trim |
| 20 | DYN | Dyne Therapeutics INC | -0.3% | -24.53% | Trim |
| 21 | CRMD | Cormedix INC | -0.4% | +18.96% | Add |
| 22 | MBX | Mbx Biosciences INC | -0.5% | -15.15% | Trim |
| 23 | APLSUSD | Apellis Pharmaceuticals INC | -0.5% | -41.52% | Trim |
| 24 | AXSM | Axsome Therapeutics INC | -0.7% | -4.35% | Trim |
| 25 | NRIX | Nurix Therapeutics INC | -0.8% | -9.82% | Trim |
| 26 | XBI | Ss Spdr S&p Biotech ETF | -0.9% | — | Unchanged |
| 27 | VRDN | Viridian Therapeutics INC | -1% | -44.79% | Trim |
| 28 | BMRN | Biomarin Pharmaceutical INC | -1.4% | -50.00% | Trim |
| 29 | MAZE | Maze Therapeutics INC | -1.4% | -18.11% | Trim |
| 30 | GPCR | Structure Therapeutics INC | -1.7% | +4.09% | Add |
| 31 | CYTK | Cytokinetics INC | -2.3% | -58.82% | Trim |
| 32 | DVAX | Dynavax Technologies CORP | — | EXIT | Sold out |
| 33 | ALMS | Alumis INC | — | NEW | New buy |
| 34 | NUVL | Nuvalent Inc-a | — | NEW | New buy |
| 35 | GMAB | Genmab A/s -sp Adr | — | NEW | New buy |
| 36 | DFTX | Definium Therapeutics INC | — | NEW | New buy |
| 37 | ATAI | Ataibeckley INC | — | NEW | New buy |
| 38 | CRVS | Corvus Pharmaceuticals INC | — | NEW | New buy |
| 39 | ACRS | Aclaris Therapeutics INC | — | NEW | New buy |
| 40 | MANE | Veradermics INC | — | NEW | New buy |
| 41 | SLDB | Solid Biosciences INC | — | NEW | New buy |
| 42 | APGE | Apogee Therapeutics INC | — | NEW | New buy |
| 43 | BRD1EUR | Mind Medicine Mindmed INC | — | EXIT | Sold out |
| 44 | KURA | Kura Oncology INC | — | NEW | New buy |
| 45 | IPSC | Century Therapeutics INC | — | NEW | New buy |
| 46 | BEAM | Beam Therapeutics INC | — | NEW | New buy |
| 47 | ATAI | AtaiBeckley Inc. | — | EXIT | Sold out |
| 48 | PSNL | Personalis INC | — | NEW | New buy |
| 49 | XENE | Xenon Pharmaceuticals INC | — | EXIT | Sold out |
| 50 | PMN | Promis Neurosciences INC | — | NEW | New buy |
Institutions with a similar AUM
CIK 0000354497
Total reported value
$6.1B
512 stks
2023-06-30
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001800798
Total reported value
$6.1B
3,368 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001733173
Total reported value
$6.1B
332 stks
2026-03-31
AUM within 0.2% of this institution
Institutions with overlapping top holdings
CIK 0001842545
Total reported value
$571.8M
28 stks
2026-03-31
2 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF
CIK 0000096223
Total reported value
$14.6B
1,692 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF
CIK 0000860645
Total reported value
$83.5M
21 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF